In8bio, Inc. (INAB)
NASDAQ:INAB
Want to see INAB full AI Analyst Report?
Top Page
IN8bio
(NASDAQ:INAB)
Select Model
Select Model
Rating:50Neutral
Price Target:
$2.00
▲(38.89% Upside)
Action:Reiterated
Date:05/09/26
The score is held back primarily by weak financial performance (no revenue, ongoing losses and negative free cash flow) and limited valuation support (negative P/E). Offsetting factors include improving cash burn and low leverage, constructive recent corporate/clinical updates and cash position, and neutral-to-slightly improving technical indicators that suggest a modest near-term rebound despite a broader downtrend.
Positive Factors
Clinical efficacy & safety
Robust repeat-dose glioblastoma data showing materially longer PFS and encouraging OS signals, plus a clean safety profile, strengthen the program's therapeutic rationale. Durable efficacy and tolerability improve prospects for regulatory engagement, investigator adoption, and potential labelable differentiation in an underserved indication.
Negative Factors
No revenue & persistent losses
As a pre-revenue developer, IN8bio lacks operating cash generation and depends on milestones or financing to sustain R&D. Persistent multi-year losses mean the company must secure external capital to continue operations, making clinical progress and funding access determinative of long-term viability.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical efficacy & safety
Robust repeat-dose glioblastoma data showing materially longer PFS and encouraging OS signals, plus a clean safety profile, strengthen the program's therapeutic rationale. Durable efficacy and tolerability improve prospects for regulatory engagement, investigator adoption, and potential labelable differentiation in an underserved indication.
Read all positive factors
IN8bio (INAB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$15.16M
Dividend YieldN/A
Average Volume (3M)70.47K
Price to Earnings (P/E)―
Beta (1Y)1.82
Revenue GrowthN/A
EPS Growth80.68%
CountryUS
Employees18
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.76
Shares Outstanding9,847,089
10 Day Avg. Volume91,864
30 Day Avg. Volume70,474
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.37
Price to Sales (P/S)0.00
P/FCF Ratio-0.81
Enterprise Value/Market Cap-0.72
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit21.84
Enterprise Value/Ebitda0.64
Forecast
1Y Price Target
$5.00Price Target Upside247.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.24
Revenue Forecast (FY)N/A
IN8bio Business Overview & Revenue Model
Company Description
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified au...
How the Company Makes Money
IN8bio does not have marketed products and, based on publicly available information, has not disclosed recurring commercial product revenue; as a clinical-stage biotech, it is primarily funded by financing activities rather than operating income. ...
IN8bio Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
52
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -500.00K | -2.50M | 0.00 | -2.50M | -1.10M | 0.00 |
| EBITDA | -17.02M | -17.36M | -26.94M | -27.51M | -27.42M | -13.87M |
| Net Income | -18.98M | -19.44M | -30.44M | -30.01M | -28.52M | -14.65M |
Balance Sheet | ||||||
| Total Assets | 26.27M | 32.28M | 20.94M | 33.71M | 33.04M | 42.22M |
| Cash, Cash Equivalents and Short-Term Investments | 21.94M | 27.09M | 11.12M | 21.28M | 18.18M | 37.02M |
| Total Debt | 2.35M | 2.78M | 5.03M | 4.89M | 5.87M | 2.41M |
| Total Liabilities | 3.48M | 4.72M | 6.47M | 8.77M | 10.31M | 4.04M |
| Stockholders Equity | 22.78M | 27.56M | 14.48M | 24.94M | 22.73M | 38.18M |
Cash Flow | ||||||
| Free Cash Flow | -14.55M | -12.71M | -24.25M | -23.94M | -27.83M | -13.82M |
| Operating Cash Flow | -14.54M | -12.71M | -24.15M | -23.34M | -24.12M | -13.51M |
| Investing Cash Flow | -9.00K | 0.00 | -187.00K | -600.00K | -3.71M | -309.00K |
| Financing Cash Flow | 24.55M | 28.64M | 14.18M | 27.04M | 8.99M | 32.95M |
IN8bio Technical Analysis
Negative
1.44
Price Trends
1.53
Positive
1.72
Negative
1.87
Negative
Market Momentum
0.02
Positive
45.33
Neutral
19.89
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INAB, the sentiment is Negative. The current price of 1.44 is below the 20-day moving average (MA) of 1.62, below the 50-day MA of 1.53, and below the 200-day MA of 1.87, indicating a neutral trend. The MACD of 0.02 indicates Positive momentum. The RSI at 45.33 is Neutral, neither overbought nor oversold. The STOCH value of 19.89 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for INAB.
IN8bio Risk Analysis
IN8bio disclosed 72 risk factors in its most recent earnings report. IN8bio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
IN8bio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $15.16M | -0.35 | -96.39% | ― | ― | 80.68% | |
50 Neutral | $21.88M | -1.33 | -74.15% | ― | -24.96% | 46.11% | |
49 Neutral | $7.65M | -3.52 | -60.33% | ― | 23.52% | 48.34% | |
49 Neutral | $9.44M | -0.50 | -87.05% | ― | -90.40% | 34.76% | |
45 Neutral | $8.69M | -0.50 | -334.42% | ― | ― | 11.71% |
* Healthcare Sector Average
INAB
IN8bio
1.45
-2.72
-65.23%
ERNA
Eterna Therapeutics
7.89
-59.61
-88.31%
QNRX
Quoin Pharmaceuticals
4.49
-4.33
-49.09%
XBIO
Xenetic Biosciences
3.09
0.13
4.39%
VYNE
VYNE Therapeutics
0.66
-0.34
-34.40%
APRE
Aprea Therapeutics
0.74
-1.01
-57.66%
IN8bio Corporate Events
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
IN8bio launches new JonesTrading at-the-market program
Neutral
Jun 1, 2026
On June 1, 2026, IN8bio, Inc. entered into a Capital on Demand Sales Agreement with JonesTrading Institutional Services LLC to establish an at-the-market equity offering program for its common stock under its existing Form S-3 shelf registration. ...
Business Operations and StrategyFinancial DisclosuresShareholder Meetings
IN8bio Reports Q1 2026 Results and Shareholder Votes
Positive
May 7, 2026
IN8bio, Inc., a clinical-stage biopharmaceutical company developing γδ T cell therapies and γδ T cell engagers for cancer and autoimmune diseases, reported first quarter 2026 results and shareholder voting outcomes on May 7, 20...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.